Mark Paradela, MD
Internal Medicine · Athens, GANPI 1437131596
Payments from drug & device makers
Across 199 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$405
- AstraZeneca$299
- Sanofi-aventis U.S. LLC$253
- Bayer$246
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$243
- GSK$242
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,58999%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 22 | $405 |
| AstraZeneca | 16 | $299 |
| Sanofi-aventis U.S. LLC | 14 | $253 |
| Bayer | 12 | $246 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $243 |
| GSK | 14 | $242 |
| Amgen | 12 | $238 |
| Lilly USA, LLC | 14 | $223 |
| AbbVie(2 entities) | 8 | $208 |
| Pfizer | 10 | $176 |
| Novo Nordisk | 9 | $148 |
| Sunovion Pharmaceuticals Inc. | 12 | $116 |
| Abbott | 5 | $108 |
| Dexcom, Inc. | 3 | $63 |
| Corcept Therapeutics | 3 | $62 |
| Exact Sciences | 3 | $60 |
| Inspire Medical Systems, Inc. | 1 | $52 |
| Sumitomo Pharma America, Inc. | 3 | $50 |
| Merck | 3 | $49 |
| Mylan Specialty L.p. | 2 | $46 |
| Seqirus USA Inc | 2 | $42 |
| Acadia Pharmaceuticals Inc | 2 | $36 |
| Ascensia Diabetes Care US Inc. | 2 | $28 |
| Corium, LLC | 1 | $28 |
| Johnson & Johnson | 2 | $27 |
| Biogen | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Novartis | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Boston Scientific | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Mannkind Corporation | 1 | $12 |
How this compares
$3,617 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 135 | $165,671 |
| TrulicityDulaglutide | 99 | $156,027 |
| OzempicSemaglutide | 108 | $146,688 |
| LinzessLinaclotide | 148 | $136,316 |
| JardianceEmpagliflozin | 100 | $106,292 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 109 | $102,904 |
| MounjaroTirzepatide | 66 | $83,759 |
| JanuviaSitagliptin Phosphate | 73 | $78,295 |
| MyrbetriqMirabegron | 114 | $74,810 |
| FarxigaDapagliflozin Propanediol | 52 | $54,263 |
| TradjentaLinagliptin | 54 | $46,132 |
| XareltoRivaroxaban | 42 | $37,038 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $24,292 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $18,972 |
| EntrestoSacubitril/Valsartan | 19 | $16,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $223 | $239,785165 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Synjardy Xr, Synjardy | $20 | $186,541199 claims |
| PfizerEliquis, Premarin | $176 | $172,067149 claims |
| Novo NordiskOzempic | $148 | $146,688108 claims |
| AbbVieLinzess | $208 | $136,316148 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $242 | $120,428141 claims |
| MerckJanuvia, Janumet Xr, Janumet | $49 | $106,034103 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $299 | $77,407107 claims |
| Astellas Pharma US IncMyrbetriq | $405 | $74,810114 claims |
| Johnson & JohnsonXarelto | $27 | $37,03842 claims |
| NovartisEntresto | $18 | $16,50019 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $253 | $13,83811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Athens
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.